Investment Rating - The report assigns a "BUY" rating to RoboSense (02498.HK) with a target price of HK$ 48.50 per share [2][7]. Core Insights - RoboSense reported strong Q4 2025 operating metrics, achieving breakeven in the quarter due to significant increases in LiDAR shipments for both ADAS and robotics [3][7]. - The robotics segment, particularly lawn mower robots, was a key driver of growth, supported by product upgrades and new customer additions [4]. - Demand for new digital LiDAR products, EMX and EM4, is expected to exceed expectations, contributing significantly to revenue in 2026 [5]. - Technological advancements showcased at CES, including a Delivery Assistant robot, highlight RoboSense's innovation capabilities [6]. - The upward revision of sales volume forecasts and revenue assumptions reflects stronger-than-expected demand, leading to improved gross margin forecasts [7]. Financial Overview - For 2025, RoboSense is projected to generate revenue of RMB 2,019.6 million, with a gross profit of RMB 557.9 million and a gross margin of 27.6% [8]. - The company anticipates a significant increase in revenue to RMB 4,002.8 million by 2026, with a gross profit of RMB 1,142.1 million [8]. - The financial metrics indicate a path to profitability, with net profit expected to turn positive by 2026, reaching RMB 221.6 million [8].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HK$ 48.50 [2][5]. Core Insights - The company achieved a breakeven point in Q4 2025, driven by strong operational performance, with ADAS lidar sales reaching 238,400 units (up 54.8% year-on-year) and robotic lidar sales soaring to 221,200 units (up 2,565.1% year-on-year) [2][5]. - The growth in robotic lidar sales is primarily attributed to the demand for lawnmower robots, with expectations for continued growth due to product upgrades and new customer acquisitions [3]. - The new digital lidar products EMX (192 lines) and EM4 (>500 lines) are expected to become major revenue sources in 2026, gradually replacing older models [4]. - The company showcased advanced technology at CES, including a delivery robot capable of performing nearly 20 complex tasks, enhancing its product matrix with new lidar products [5]. Financial Summary - Revenue projections for the company are as follows: RMB 1,648.9 million for 2024, RMB 2,019.6 million for 2025, RMB 4,002.8 million for 2026, and RMB 5,147.3 million for 2027, reflecting a growth rate of 47.2% in 2024 and 22.5% in 2025 [13]. - Gross profit is expected to increase from RMB 283.6 million in 2024 to RMB 1,445.4 million in 2027, with gross margins improving from 17.2% to 28.1% over the same period [13]. - The company anticipates a net profit of RMB 221.6 million in 2026 and RMB 421.9 million in 2027, following a loss of RMB 481.8 million in 2024 and a reduced loss of RMB 239.2 million in 2025 [6][13].

Investment Rating - The report assigns a "Buy" rating to Shanghai Baoji Pharmaceutical with a target price of HK$ 111.30 [2][6]. Core Insights - Shanghai Baoji Pharmaceutical (02659.HK) is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using synthetic biology technology, targeting complex diseases with limited treatment options [3][12]. - The company has established a product pipeline consisting of one approved drug and seven candidates in clinical stages, along with four preclinical assets [3][12]. - The company aims to address the pain points of traditional pharmaceuticals by producing biopharmaceuticals that can replace biochemical extraction products derived from animal organs, blood, or urine [5][12]. Business Overview - The company is currently focused on four strategic therapeutic areas: i) large-volume subcutaneous administration, ii) antibody-mediated autoimmune diseases, iii) assisted reproductive drugs, and iv) other recombinant bioproducts [3][12]. - The company has a clear commercialization model and timeline, expecting significant revenue contributions starting in 2026 from its core products KJ017 and SJ02, with KJ103 anticipated to contribute from 2027 [4][12]. Product Development - KJ017, a key product, is a highly glycosylated recombinant hyaluronidase designed for subcutaneous drug delivery, expected to receive NDA approval in Q1 2026 [8][22]. - KJ103, a recombinant IgG degrading enzyme, is the only product of its kind expected to be launched in China, targeting autoimmune diseases and transplant desensitization [8][31]. - SJ02, a long-acting recombinant FSH product, has been approved for marketing and is expected to significantly improve patient outcomes in assisted reproduction [39][40]. Financial Projections - The company forecasts revenues of HK$ 6.9 million in 2024, increasing to HK$ 530 million by 2027, with a gross margin projected to decline from 97.8% in 2024 to 82.7% in 2027 [6][10]. - The company is expected to incur net losses in the coming years, with projected losses of HK$ 160.4 million in 2024 and HK$ 30.8 million in 2027 [6][10]. Market Position - The company has a first-mover advantage in China for its core products, which have already been commercialized in some foreign markets, indicating a strong market demand [4][12]. - The company has established partnerships with other pharmaceutical and biotechnology firms to develop subcutaneous drug delivery solutions, enhancing its market presence [26][29].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HK$ 43.50 [2][4]. Core Insights - In 2024, the company is expected to achieve a revenue growth of 47.2%, reaching RMB 1.648 billion, with 93.0% of revenue derived from sales of lidar used in ADAS, robotics, and other applications [2][3]. - The gross margin for 2024 is projected to improve significantly to 17.2%, while the net loss is expected to narrow to RMB 480 million [2][4]. - The company plans to offer customizable solutions to meet diverse customer needs, particularly in the automotive market, where there is a higher demand for cost-performance balance [4]. Revenue and Financial Performance - The company’s revenue for 2024 is projected at RMB 1,648.9 million, with a year-on-year growth of 47.2% [10]. - The gross profit is expected to be RMB 283.6 million, with a gross margin of 17.2% [10]. - The net loss for 2024 is anticipated to be RMB 481.8 million, improving in subsequent years to a profit of RMB 446.1 million by 2026 [10]. Market Position and Competitive Landscape - The company maintains a strong R&D capability, allowing it to adapt to market trends and provide competitive solutions [4]. - The lidar market for ADAS remains highly concentrated, which helps OEMs maintain balance and mitigate supply chain risks [4]. - The sales volume of lidar for ADAS in Q4 2024 is reported at 153,900 units, with expectations for gradual growth despite increased competition [3]. Product Development and Future Outlook - The company has over 100 models with mass production orders as of March 31, 2025, indicating strong market penetration [3]. - The recently launched EM4 lidar, featuring 1080 lines and a detection range of 600 meters, enhances the product portfolio [3]. - The company is optimistic about the growth of lidar shipments for robotics, with a sales target of 8,300 units in Q4 2024 [3].

Investment Rating - The report assigns a "BUY" rating to RoboSense (02498.HK) with a target price of HK$ 43.50 [2][6]. Core Insights - RoboSense reported a year-on-year revenue increase of 47.2%, reaching RMB 1,648.9 million in 2024, with 93.0% of revenue coming from LIDAR sales for ADAS, robotics, and other applications [2][6]. - The gross margin improved significantly to 17.2%, while the net loss narrowed to RMB 481.8 million [2][6]. - The company is well-positioned to maintain its leadership in the LiDAR sector, with expectations of achieving break-even by 2026 [6]. Revenue and Growth - Revenue for 2024 was RMB 1,648.9 million, with projected revenues of RMB 2,502.7 million in 2025, RMB 3,425.3 million in 2026, and RMB 5,199.2 million in 2027 [7][13]. - The year-on-year growth rates are projected at 51.8% for 2025, 36.9% for 2026, and 51.8% for 2027 [13]. Product Performance - In Q4 2024, RoboSense sold 153,900 units of LIDAR for ADAS, with the M1P model being the primary revenue driver, while the MX model is expected to gain traction [4][6]. - The company achieved sales of 8,300 units of LIDAR for robotics in Q4 2024, with growth anticipated from the E1R model and other new models [5][6]. Market Position and Strategy - RoboSense's strong R&D capabilities allow it to adapt to market trends and offer competitive solutions, focusing on customizable solutions for diverse applications [6]. - The ADAS LiDAR market is characterized by concentration and oligopoly, enabling OEMs to mitigate concentration risks effectively [6]. Financial Metrics - The gross profit for 2024 was RMB 283.6 million, with a gross margin of 17.2% [13][14]. - The report indicates a projected improvement in gross margin to 21.6% in 2025 and 24.9% in 2026 [13][14].

Investment Rating - The report does not provide a specific investment rating for the company [4] Core Insights - The company is expected to achieve a turnaround and consider dividend distribution once its related business becomes profitable [2][98] - The acquisition of BTHL has increased the company's stake to 70%, enhancing its revenue and cash flow sources [2][12] - A fare adjustment of 7.5% for city and New Territories routes has been approved, effective January 5, 2025, which is anticipated to positively impact profitability [2][90] Business Overview - The company, through its subsidiary Glorify, acquired approximately 54.44% of BTHL for HK$ 2.72 billion, raising its ownership to 70% [2][12] - BTHL focuses on providing public bus and tourism-related services under the Citybus brand and is the exclusive advertising agent for Citybus vehicle advertising [2][12] - The merger of Citybus and Newbus is expected to optimize routes, enhance operational efficiency, and reduce costs [3][7] Financial Data and Peer Comparison - BTHL generated total revenue of HK$ 34.9 billion in 2023, accounting for 78.6% of the group's total revenue [98] - The company has a market capitalization of approximately HK$ 1 billion, with a potential dividend yield of 6% to 7% based on a 95% profit distribution [2][98] - The financial performance of the bus industry improved significantly in 2023, with a recovery in passenger numbers post-pandemic [98][101] Industry Overview - The Hong Kong public bus industry consists of both franchised and non-franchised bus services, with franchised buses serving areas not easily accessible by rail [60] - The number of franchised bus routes in Hong Kong increased from 670 in 2018 to 750 in 2023, with Citybus operating 233 routes [60][92] - The industry size was approximately HK$ 10.64 billion in 2023, with Citybus holding a market share of about 27.9% [92][93]

Investment Rating - The report does not provide a specific investment rating for the company [4] Core Insights - The company, Hans Group Holdings (00554.HK), has acquired an additional 54.44% stake in BTHL for HK$ 2.72 billion, increasing its ownership to 70% [2][12] - The acquisition is expected to lead to a turnaround and potential dividend distribution, with a 7.5% fare increase approved for Citybus routes, effective January 5, 2025, which is anticipated to have a minimal impact on demand [2][98] - The merger of Citybus and New World First Bus is expected to enhance operational efficiency and reduce costs through route optimization and resource sharing [3][7] Business Overview - The acquisition of BTHL is valued at approximately HK$ 5.0 billion, with HK$ 500 million paid in cash and HK$ 220 million in shares [12] - BTHL focuses on providing public bus and tourism-related services in Hong Kong, as well as advertising services [13] - Citybus operates 233 franchised bus routes, with a fleet of 1,495 licensed buses, primarily serving the Hong Kong Island area [23] Financial Data and Peer Comparison - In 2023, BTHL generated total revenue of HK$ 3.49 billion, accounting for 78.6% of the group's total revenue [98] - The company reported a net loss of HK$ 73.6 million in 2023, with an operating profit margin of 3.4% [101] - The financial performance of the franchised bus industry improved significantly in 2023, with a recovery in passenger numbers post-pandemic [101] Industry Overview - The Hong Kong franchised bus industry is projected to reach a market size of approximately HK$ 10.64 billion in 2023, with Citybus holding a market share of about 27.9% [92] - The number of franchised bus routes in Hong Kong increased from 670 in 2018 to 750 in 2023, with Citybus routes growing from 205 to 233 [60] - The report highlights that the demand for franchised bus services remains relatively inelastic, suggesting that fare increases will not significantly affect ridership [98]

Investment Rating - The report assigns a stock rating of NR (Not Rated) for Hans Group Holdings Limited (00554.HK) [6] Core Insights - The acquisition of 54.44% of BTHL by Hans Group for HKD 2.7 billion increases its stake to 70%, with BTHL valued at approximately HKD 5 billion [4][15] - A fare adjustment of 7.5% for Citybus routes is expected to help the company return to profitability by increasing revenue without significantly impacting demand [5][90] - The potential for dividend distribution exists if Citybus achieves net profit, with a possible yield of 6% to 7% based on a 95% payout ratio [5][90] Business Overview - BTHL provides public bus services under the Citybus brand, including advertising and tourism services [4][15] - The company operates a fleet of 1,495 buses across 233 routes, with a significant increase in passenger numbers post-pandemic [25][26][68] Financial Performance - BTHL reported total revenue of HKD 34.9 billion in 2023, a 35.1% increase year-on-year, with ticket revenue contributing 87.3% of total income [26][46] - The company aims to improve operational efficiency and reduce costs through the merger with NWFB, which is expected to optimize routes and enhance resource utilization [7][97] Industry Overview - The Hong Kong franchised bus industry is dominated by four operators, with Citybus being the sole operator for routes on Hong Kong Island [58] - The industry faced challenges during the pandemic but is recovering, with a projected market size of HKD 10.6 billion in 2023 [86] Investment Thesis - The anticipated fare increase and potential for dividend distribution are key factors for investment consideration, as Citybus is the main revenue source for Hans Group [90] - The merger with NWFB is expected to create synergies and improve financial performance through cost savings and operational efficiencies [97]

Investment Rating - The report does not provide a specific investment rating for Hans Group Holdings (00554.HK) [5] Core Insights - Hans Group Holdings acquired a 54.44% stake in BTHL for HKD 2.7 billion, increasing its ownership to 70% [2][12] - The fare adjustment of 7.5% for Citybus is expected to facilitate a financial turnaround and potential dividend distributions [3][91] - The merger between Citybus and NWFB is anticipated to create economies of scale and operational synergies [4][96] Business Overview - Hans Group Holdings primarily provides integrated facilities for petroleum and liquid chemicals, including terminal storage and trading services [52] - BTHL, a subsidiary of Hans, specializes in public bus services in Hong Kong, operating under the Citybus brand [14][18] - The acquisition of BTHL is valued at approximately HKD 5.0 billion, with a structured payment plan [12] Financial Performance - BTHL generated HKD 3.49 billion in revenue in 2023, accounting for 78.6% of the Group's total revenue [91] - The fare revenue from BTHL increased by 35.1% year-on-year, reaching HKD 3.0 billion in 2023 [24][45] - The Group's market capitalization is approximately HKD 1 billion, with potential dividend returns estimated at 6% - 7% based on net profit [3][91] Industry Overview - The franchised bus industry in Hong Kong is valued at HKD 10.6 billion, with BTHL holding a 27.9% market share [87] - The number of franchised bus routes increased from 670 in 2018 to 750 in 2023, with Citybus operating 233 routes [61][62] - The number of franchised bus passengers rebounded to 1.34 billion in 2023, although still below pre-pandemic levels [66] Investment Thesis - The anticipated fare adjustment is expected to positively impact Citybus's financial performance and facilitate dividend distributions [91] - The merger with NWFB is projected to enhance operational efficiency and reduce costs through resource sharing [96][98] - The Group's reliance on Citybus as its primary revenue stream positions it favorably for future growth [91]

Investment Rating - The investment rating for EEKA Fashion is "BUY" with a target price of HK$ 11.88 [6]. Core Insights - The company is expected to experience a less than 5% year-over-year decrease in revenue and a decline of less than 45% in net profit for the year ending December 2024, indicating stronger headwinds than previously estimated [1]. - The retail environment in the second half of 2024 is projected to remain stagnant, with garment sales in China experiencing a slight decline due to a high base effect from 2023 and disappointing sales attributed to unseasonably warm weather [2]. - Despite short-term setbacks, the company is committed to its "affordable luxury" positioning and will continue to invest in marketing, which has contributed to the decline in net profit [3]. - The company has made progress in inventory management, and stock clearance is not expected to be a significant issue in FY 2025, with a focus on boosting sales as the top priority [5]. Financial Performance Summary - For the year 2024, EEKA Fashion's revenue is projected to be RMB 6,606.9 million, down from RMB 6,912.3 million in 2023, reflecting a year-over-year decline of 4.4% [14]. - The net profit for 2024 is estimated at RMB 485.2 million, a significant decrease of 41.7% compared to RMB 832.6 million in 2023 [14]. - The gross margin is expected to remain stable at around 75.9% for the upcoming years, indicating a historically high level [14]. - The company plans to maintain marketing expenses at 3% - 4% of total revenue, despite the need for slight adjustments to contain costs [3]. Market Context - The market capitalization of EEKA Fashion is approximately HK$ 6.1 billion, with a current price of HK$ 8.61, reflecting a significant drop from its 52-week high of HK$ 14.04 [6]. - The company’s performance relative to the Hang Seng Index has been poor, with a 1-year relative performance of -62.3% [6]. - The retail sales of department stores in China have declined by 2.4% year-over-year, impacting key sales channels for the company's primary brand, Koradior, which accounts for over one-third of total sales [2].